Get the Stockscreener App
4.32
16.44%
0.61
Insight Molecular Diagnostics Inc stock is traded at $4.32, with a volume of 331.61K.
It is up +16.44% in the last 24 hours and down -3.14% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
See More
Previous Close:
$3.71
Open:
$3.76
24h Volume:
331.61K
Relative Volume:
1.24
Market Cap:
$141.37M
Revenue:
$1.95M
Net Income/Loss:
$-47.84M
P/E Ratio:
-2.9126
EPS:
-1.4832
Net Cash Flow:
$-27.46M
1W Performance:
-10.56%
1M Performance:
-3.14%
6M Performance:
-22.44%
1Y Performance:
+80.00%
1-Day Range:
$3.76
$4.36
1-Week Range:
$3.54
$4.93
52-Week Range:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.32 | 147.26M | 1.95M | -47.84M | -27.46M | -1.4832 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Doctors to discuss in-house heart transplant testing Aug. 17 - Stock Titan
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
IMDX Looks 284.7% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay - TipRanks
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Insight Molecular Q2 EPS beats as FDA review advances - scanx.trade
Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results - Investing.com
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates - Investing.com
Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com - Investing.com South Africa
Insight Molecular Diagnostics: Q2 Earnings Snapshot - marketscreener.com
IMDX: FDA review progresses, Medicare expands coverage, and Q2 loss narrows on cost discipline - TradingView
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - GlobeNewswire
iMDx CEO and CFO Plan Aug. 11 Virtual Investor Meetings - Stock Titan
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
IMDX Looks 289.5% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
IMDX Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Earnings Preview: IMDX to Report Financial Results Post-market on August 10 - Moomoo
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - The Manila Times
IMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - marketscreener.com
iMDx to Release Second Quarter Results on August 10, 2026 - GlobeNewswire
Insight Molecular Diagnostics Inc. Revenue Breakdown – NASDAQ:IMDX - TradingView
IMDX Q2'26 Earnings: revenue estimate is 437.50K USD - TradingView
IMDX|Insight Molecular Diagnostics Ord Shs|Price:4.700|Chg%:-0.040 - TradingKey
CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion - insights.citeline.com
Insight Molecular Diagnostics Inc. Revenue Breakdown – LSE:0KCC - TradingView
Insight Molecular Diagnostics Ord Shs (IMDX) Institutional Confidence - TradingKey
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMDX|Insight Molecular Diagnostics Ord Shs|Price:4.960|Chg%:-0.030 - TradingKey
Insight Molecular Diagnostics Inc. (IMDX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insight Molecular Diagnostics (IMDX) Showcases Promising Study o - GuruFocus
Insight Molecular Diagnostics Inc. Highlights Lancet Group Publication Demonstrating GraftAssure Assay?s Role In Guiding Kidney Transplant Drug Use - marketscreener.com
Medicare coverage confirmed for iMDx kidney-rejection monitoring test - Stock Titan
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication - GlobeNewswire
Enterprise value to revenue forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
MOLN Stock Price and Chart — NASDAQ:MOLN - TradingView
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - Sahm
IMDX Q1 2026 Earnings: Narrowing Losses and Cost Discipline Signal ProgressEstimate Accuracy - po-news-eg.net
Insight Molecular Diagnostics Inc. Announces Favorable Medicare Coverage Decision Supporting Commercial Adoption Of GraftAssure Assay Portfolio - marketscreener.com
Medicare expands coverage for transplant monito... - Pluang
iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing - Quiver Quantitative
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - GlobeNewswire Inc.
New Medicare policy allows more donor-DNA tests after transplants - Stock Titan
Price to book forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Enterprise value to EBIT forward of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):